Market Place
Sourcing Support
PharmaCyte Invests $7M In Inflammatory Disease Firm MyMD
21 May 2024 //
BUSINESSWIRE
Femasys Secures Additional Financing with Strategic Investment from Investors
15 Nov 2023 //
GLOBENEWSWIRE
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
31 Oct 2023 //
BUSINESSWIRE
PharmaCyte Announces Cash Tender Offer for 7,750,000 Shares at $3.25 Per Share
11 May 2023 //
BUSINESSWIRE
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
02 Feb 2023 //
BUSINESSWIRE
PharmaCyte CEO exits amid strategic review, clinical hold
07 Oct 2022 //
FIERCEBIOTECH
PharmaCyte Biotech Board of Directors Announces Business Review Committee
07 Oct 2022 //
GLOBENEWSWIRE
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
15 Aug 2022 //
BUSINESSWIRE
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
28 Jul 2022 //
BUSINESSWIRE
Iroquois Files PCM to Reconstitute Board of Directors at PharmaCyte Biotech
28 Jul 2022 //
PRNEWSWIRE
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
21 Jul 2022 //
BUSINESSWIRE
PharmaCyte Reports +ve Interim Results in Malignant Ascites Mouse Model Study
19 Jul 2022 //
BUSINESSWIRE
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results
11 Jul 2022 //
BUSINESSWIRE
PharmaCyte Biotech Announces Additional QC Assay and Confirms Stability
05 Jul 2022 //
BUSINESSWIRE
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter
15 Jun 2022 //
BUSINESSWIRE
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
13 Jun 2022 //
BUSINESSWIRE
PharmaCyte Biotech Issues Response to Iroquois Capital Letter
08 Jun 2022 //
BUSINESSWIRE
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
02 Jun 2022 //
BUSINESSWIRE
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy
23 May 2022 //
BUSINESSWIRE
PharmaCyte Bio to Attend 15th International Conference on Advanced Technologies
27 Apr 2022 //
BUSINESSWIRE
PharmaCyte Biotech Announces Positive Tests Results for Pancreatic Cancer Trial
19 Apr 2022 //
BUSINESSWIRE
PharmaCyte to Accelerate Preparations for Start of Pancreatic Cancer Trial
13 Apr 2022 //
BUSINESSWIRE
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors
05 Apr 2022 //
BUSINESSWIRE
PharmaCyte Biotech Successfully Completes 24-Month Stability Study
22 Mar 2022 //
BUSINESSWIRE
PharmaCyte Biotech Reports Third Quarter Financial Results
16 Mar 2022 //
BUSINESSWIRE
PharmaCyte Announces Genetic Stability of Cytochrome P450 Gene
22 Feb 2022 //
BUSINESSWIRE
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
14 Feb 2022 //
BUSINESSWIRE
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
06 Jan 2022 //
BUSINESSWIRE
PharmaCyte Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
04 Jan 2022 //
BUSINESSWIRE
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement
30 Nov 2021 //
BUSINESSWIRE
PharmaCyte Shows More Positive Results From FDA-Required Biocompatibility Tests
21 Sep 2021 //
BUSINESSWIRE
PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA
16 Sep 2021 //
BUSINESSWIRE
PharmaCyte Biotech to Participate in H.C. Wainwright Investment Conference
08 Sep 2021 //
BUSINESSWIRE
PharmaCyte Biotech Expands Product Pipeline Following $90-Million Capital Raise
25 Aug 2021 //
BUSINESSWIRE
PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering
23 Aug 2021 //
BUSINESSWIRE
PharmaCyte Biotech Announces Closing of $15-Million Public Offering
12 Aug 2021 //
BUSINESSWIRE
PharmaCyte Biotech Announces Uplist Date Pricing of $15 Million IPO
09 Aug 2021 //
BUSINESSWIRE
PharmaCyte Biotech Announces Launch of Public Offering
02 Aug 2021 //
BUSINESS WIRE
PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts
23 Jul 2021 //
BUSINESSWIRE
PharmaCyte Biotech Announces Stability Test Results on Cells
14 Jul 2021 //
BUSINESS WIRE
PharmaCyte Biotech Announces Stability Test Results on Cells
14 Jul 2021 //
BUSINESS WIRE
PharmaCyte Biotech Announces Stability Test Results
13 Jul 2021 //
BUSINESSWIRE
PharmaCyte Biotech Announces Stability Test Results on Cells
12 Jul 2021 //
BUSINESSWIRE
PharmaCyte Biotech Announces Reverse Stock Split
09 Jul 2021 //
BUSINESSWIRE
PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold
26 Jun 2021 //
BUSINESSWIRE
PharmaCyte Biotech Announces Shareholders Vote
23 Jun 2021 //
BUSINESSWIRE
PharmaCyte Announces Adjournment of Annual Meeting of Stockholders
18 Jun 2021 //
BUSINESSWIRE
PharmaCyte Biotech Announces Details to Virtual Annual Meeting of Shareholders
14 Jun 2021 //
BUSINESSWIRE
PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA
26 Jan 2021 //
BUSINESSWIRE
PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA
14 Dec 2020 //
BUSINESSWIRE
PharmaCyte Biotech Successfully Completes 9-Month Stability Study
02 Dec 2020 //
COM
PharmaCyte Biotech’s Investigational New Drug Application Placed
02 Oct 2020 //
BUSINESSWIRE
PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period
23 Sep 2020 //
BUSINESSWIRE
PharmaCyte Biotech Successfully Completes Six-Month Stability Study
14 Sep 2020 //
PHARMACYTE
PharmaCyte Biotech completes second container closure integrity test
09 Sep 2020 //
PHARMABIZ
PharmaCyte Successfully Completes Second Container Closure Integrity Test
08 Sep 2020 //
PRESS RELEASE
PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial
02 Sep 2020 //
BIOSPACE
PharmaCyte Biotech Announces Submission of Drug Master File to FDA
27 Jul 2020 //
BUSINESSWIRE
